Sumitomo Chemical (4005 JP), a Japanese chemicals group, and its separately listed pharmaceutical subsidiary Sumitomo Pharma (4506 JP) face disputed short-seller claims about earnings quality and regenerative-medicine prospects. The latest distinct issue is Gotham City Research’s 7-Aug-2026 challenge to research integrity at Pharma’s partner, CiRA, and the foundations of its AMCHEPRY programme. Pharma rejected the implications on 12-Aug-2026, citing regulatory review and continuing clinical studies. The earlier Swiss-accounting allegation was substantially answered by the company’s reconciliation, although disposal gains and rising receivables still warrant scrutiny. The reviewed sources do not establish financial-statement fraud at either issuer or that AMCHEPRY’s regulatory submission contained falsified data.

The information on this page has been compiled from publicly available sources. GMT Research Limited has not verified the information and does not warrant its accuracy. Any claims made or views expressed are not necessarily those of GMT Research Limited.